DALLAS & MARTINSRIED, Germany - Celanese Corporation (NYSE: NYSE:CE), a global specialty materials and chemical company, has entered into a research collaboration with Secarna Pharmaceuticals GmbH & Co. KG to develop long-acting implants for the delivery of antisense oligonucleotides (ASOs). These implants aim to improve patient outcomes across various diseases by reducing dosing frequency and minimizing immune responses.
ASOs are synthetic molecules that inhibit the production of disease-related proteins by targeting specific messenger RNA. This therapeutic approach has been commercially validated but often requires frequent administration or large doses, which can burden patients.
The collaboration will leverage Celanese's VitalDose® Drug Delivery Platform with Secarna’s proprietary ASO Drug Discovery (NASDAQ:WBD) and Development Platform. The VitalDose® technology is known for its reliable controlled-release performance and is used in approved drug products in the U.S. and Europe, capable of delivering medications for extended periods, up to years.
Cyonna Holmes, global business strategy leader for Ophthalmology and RNA at Celanese, expressed enthusiasm about developing an innovative implant that could transform the administration of disease-modifying ASO therapies. Secarna’s CBO, Konstantin Petropoulos, echoed this sentiment, highlighting the goal to provide highly specific, potent, safe, and convenient therapeutic options to patients in need.
The Celanese Development & Feasibility Lab will conduct parts of the research independently in their pharmaceutical facility.
Celanese, a Fortune 500 company with net sales of $10.9 billion in 2023, is recognized for creating specialty material solutions for a wide range of industries, focusing on sustainability and community impact. Secarna Pharmaceuticals is a leader in antisense drug discovery and development in Europe, working on over 20 programs that target various diseases.
This collaboration represents a significant step in advancing drug delivery technologies and underscores the commitment of both companies to enhancing patient care through innovation. The information for this article is based on a press release statement.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.